<p>Fulcrum Therapeutics（纳斯达克股票代码：FULC - 获取免费报告）在周日发布给客户和投资者的研究报告中，被华尔街 Zen 的投资分析师从 “卖出” 评级下调至 “强烈卖出” 评级。</p>
<p>获取 <strong>Fulcrum Therapeutics</strong> 的提醒：</p>
<p>其他一些股票研究分析师也最近对该公司发表了评论。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Fulcrum Therapeutics 股票的 “卖出（d-）” 评级。Truist Financial 在 2 月 24 日的研究报告中对 Fulcrum Therapeutics 设定了 17.00 美元的目标价。摩根大通在 1 月 12 日的研究报告中开始覆盖 Fulcrum Therapeutics。他们对该股票给予了 “增持” 评级，并设定了 20.00 美元的目标价。最后，Leerink Partners 在 2 月 24 日的研究报告中重申了对 Fulcrum Therapeutics 股票的 “跑赢大盘” 评级。七位研究分析师对该股票给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，Fulcrum Therapeutics 的共识评级为 “适度买入”，平均目标价为 19.00 美元。</p>
<p><strong>获取我们关于 Fulcrum Therapeutics 的最新报告</strong></p>
<h2>Fulcrum Therapeutics 价格表现</h2>
<p>纳斯达克：FULC 的股票在周五开盘价为 7.55 美元。Fulcrum Therapeutics 的 1 年最低价为 2.54 美元，1 年最高价为 15.74 美元。该公司的市值为 5.0283 亿美元，市盈率为-6.40，贝塔值为 3.27。该公司的 50 日移动平均线为 8.60 美元，200 日移动平均线为 9.64 美元。</p>
<p>Fulcrum Therapeutics（纳斯达克：FULC - 获取免费报告）最后一次发布财报是在 2 月 24 日。该公司报告季度每股收益为（0.31 美元），符合分析师的共识预期（0.31 美元）。分析师平均预计 Fulcrum Therapeutics 在当前年度的每股收益为-0.16 美元。</p>
<h2>机构资金流入和流出</h2>
<p>几家机构投资者和对冲基金最近买入和卖出了该股票的股份。Suvretta Capital Management LLC 在第四季度将其在 Fulcrum Therapeutics 的股份增加了 21.9%。Suvretta Capital Management LLC 现在拥有 6,561,111 股该公司的股票，价值 74,206,000 美元，在上个季度又购买了 1,180,111 股。Nantahala Capital Management LLC 在第三季度将其在 Fulcrum Therapeutics 的股份增加了 8.9%。Nantahala Capital Management LLC 现在拥有 4,670,784 股该公司的股票，价值 42,971,000 美元，在上个季度又购买了 382,485 股。Adage Capital Partners GP L.L.C.在第二季度将其在 Fulcrum Therapeutics 的股份增加了 53.0%。Adage Capital Partners GP L.L.C.现在拥有 4,589,000 股该公司的股票，价值 31,572,000 美元，在上个季度又购买了 1,589,000 股。Braidwell LP 在第四季度将其在 Fulcrum Therapeutics 的股份增加了 1,294.7%。Braidwell LP 现在拥有 3,061,222 股该公司的股票，价值 34,622,000 美元，在上个季度又购买了 2,841,734 股。最后，Siren L.L.C.在第四季度获得了 Fulcrum Therapeutics 的新头寸，价值 22,054,000 美元。89.83% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Fulcrum Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Fulcrum Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于发现和开发通过表观遗传控制调节基因表达的精准药物。Fulcrum 利用其专有的靶点发现平台，旨在识别小分子治疗药物，以恢复因基因失调引起的疾病中的正常基因功能。该公司的核心研究工作集中在转录调节因子和染色质修饰蛋白上，旨在解决潜在的疾病机制，而不是下游症状。</p>
<p>Fulcrum 最先进的项目包括 FTX-6058，这是一种口服治疗候选药物，旨在提高镰状细胞病和β-地中海贫血患者的胎儿血红蛋白水平，以及一个针对面肩肱肌营养不良症（FSHD）的临床前项目，通过抑制一种关键的表观遗传驱动因子来靶向异常基因表达。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票，胜过 Fulcrum Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RlVMQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RlVMQw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Fulcrum Therapeutics 吗？</h2>
<p>在你考虑 Fulcrum Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Fulcrum Therapeutics 并不在名单上。</p>
<p>虽然 Fulcrum Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - Vanguard

医疗业 ETF - SPDR

<p>华尔街禅将 Fulcrum Therapeutics (NASDAQ:FULC) 的评级从 “卖出” 下调至 “强烈卖出”。其他分析师也对该股票发表了评论，Weiss Ratings 维持 “卖出 (d-)” 评级，而 Truist Financial 则设定了 17.00 美元的目标价。Fulcrum 的股票开盘价为 7.55 美元，1 年最低价为 2.54 美元，最高价为 15.74 美元。该公司报告的每股收益为（0.31 美元），符合预期。机构投资者持有该股票的 89.83%，Fulcrum 专注于开发针对遗传疾病的精准医疗</p>

<p>Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a &#34;sell&#34; rating to a &#34;strong sell&#34; rating in a research report issued to clients and investors on Sunday.</p>
<div class="lb-trans"><p>Fulcrum Therapeutics（纳斯达克股票代码：FULC - 获取免费报告）在周日发布给客户和投资者的研究报告中，被华尔街 Zen 的投资分析师从 “卖出” 评级下调至 “强烈卖出” 评级。</p>
</div><p>Get <strong>Fulcrum Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Fulcrum Therapeutics</strong> 的提醒：</p>
</div><p>A number of other equities research analysts also recently commented on the company. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Fulcrum Therapeutics in a research report on Thursday, January 22nd. Truist Financial set a $17.00 target price on Fulcrum Therapeutics in a research report on Tuesday, February 24th. JPMorgan Chase &amp; Co. initiated coverage on Fulcrum Therapeutics in a research report on Monday, January 12th. They issued an &#34;overweight&#34; rating and a $20.00 target price on the stock. Finally, Leerink Partners restated an &#34;outperform&#34; rating on shares of Fulcrum Therapeutics in a research report on Tuesday, February 24th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, Fulcrum Therapeutics has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $19.00.</p>
<div class="lb-trans"><p>其他一些股票研究分析师也最近对该公司发表了评论。Weiss Ratings 在 1 月 22 日的研究报告中重申了对 Fulcrum Therapeutics 股票的 “卖出（d-）” 评级。Truist Financial 在 2 月 24 日的研究报告中对 Fulcrum Therapeutics 设定了 17.00 美元的目标价。摩根大通在 1 月 12 日的研究报告中开始覆盖 Fulcrum Therapeutics。他们对该股票给予了 “增持” 评级，并设定了 20.00 美元的目标价。最后，Leerink Partners 在 2 月 24 日的研究报告中重申了对 Fulcrum Therapeutics 股票的 “跑赢大盘” 评级。七位研究分析师对该股票给予了买入评级，一位给予了持有评级，两位给予了卖出评级。根据 MarketBeat 的数据，Fulcrum Therapeutics 的共识评级为 “适度买入”，平均目标价为 19.00 美元。</p>
</div><p><strong>Get Our Latest Report on Fulcrum Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Fulcrum Therapeutics 的最新报告</strong></p>
</div><h2>Fulcrum Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Fulcrum Therapeutics 价格表现</h2>
</div><p>Shares of NASDAQ:FULC opened at $7.55 on Friday. Fulcrum Therapeutics has a 1 year low of $2.54 and a 1 year high of $15.74. The firm has a market capitalization of $502.83 million, a P/E ratio of -6.40 and a beta of 3.27. The business's 50-day moving average is $8.60 and its 200 day moving average is $9.64.</p>
<div class="lb-trans"><p>纳斯达克：FULC 的股票在周五开盘价为 7.55 美元。Fulcrum Therapeutics 的 1 年最低价为 2.54 美元，1 年最高价为 15.74 美元。该公司的市值为 5.0283 亿美元，市盈率为-6.40，贝塔值为 3.27。该公司的 50 日移动平均线为 8.60 美元，200 日移动平均线为 9.64 美元。</p>
</div><p>Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported ($0.31) EPS for the quarter, meeting analysts' consensus estimates of ($0.31). On average, analysts expect that Fulcrum Therapeutics will post -0.16 EPS for the current year.</p>
<div class="lb-trans"><p>Fulcrum Therapeutics（纳斯达克：FULC - 获取免费报告）最后一次发布财报是在 2 月 24 日。该公司报告季度每股收益为（0.31 美元），符合分析师的共识预期（0.31 美元）。分析师平均预计 Fulcrum Therapeutics 在当前年度的每股收益为-0.16 美元。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the stock. Suvretta Capital Management LLC grew its stake in Fulcrum Therapeutics by 21.9% during the 4th quarter. Suvretta Capital Management LLC now owns 6,561,111 shares of the company's stock worth $74,206,000 after purchasing an additional 1,180,111 shares in the last quarter. Nantahala Capital Management LLC grew its stake in Fulcrum Therapeutics by 8.9% during the 3rd quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company's stock worth $42,971,000 after purchasing an additional 382,485 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its stake in Fulcrum Therapeutics by 53.0% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,589,000 shares of the company's stock worth $31,572,000 after purchasing an additional 1,589,000 shares in the last quarter. Braidwell LP grew its stake in Fulcrum Therapeutics by 1,294.7% during the 4th quarter. Braidwell LP now owns 3,061,222 shares of the company's stock worth $34,622,000 after purchasing an additional 2,841,734 shares in the last quarter. Finally, Siren L.L.C. acquired a new position in Fulcrum Therapeutics during the 4th quarter worth $22,054,000. 89.83% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买入和卖出了该股票的股份。Suvretta Capital Management LLC 在第四季度将其在 Fulcrum Therapeutics 的股份增加了 21.9%。Suvretta Capital Management LLC 现在拥有 6,561,111 股该公司的股票，价值 74,206,000 美元，在上个季度又购买了 1,180,111 股。Nantahala Capital Management LLC 在第三季度将其在 Fulcrum Therapeutics 的股份增加了 8.9%。Nantahala Capital Management LLC 现在拥有 4,670,784 股该公司的股票，价值 42,971,000 美元，在上个季度又购买了 382,485 股。Adage Capital Partners GP L.L.C.在第二季度将其在 Fulcrum Therapeutics 的股份增加了 53.0%。Adage Capital Partners GP L.L.C.现在拥有 4,589,000 股该公司的股票，价值 31,572,000 美元，在上个季度又购买了 1,589,000 股。Braidwell LP 在第四季度将其在 Fulcrum Therapeutics 的股份增加了 1,294.7%。Braidwell LP 现在拥有 3,061,222 股该公司的股票，价值 34,622,000 美元，在上个季度又购买了 2,841,734 股。最后，Siren L.L.C.在第四季度获得了 Fulcrum Therapeutics 的新头寸，价值 22,054,000 美元。89.83% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Fulcrum Therapeutics</h2>
<div class="lb-trans"><h2>关于 Fulcrum Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company's core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.</p>
<div class="lb-trans"><p>Fulcrum Therapeutics, Inc 是一家临床阶段的生物制药公司，专注于发现和开发通过表观遗传控制调节基因表达的精准药物。Fulcrum 利用其专有的靶点发现平台，旨在识别小分子治疗药物，以恢复因基因失调引起的疾病中的正常基因功能。该公司的核心研究工作集中在转录调节因子和染色质修饰蛋白上，旨在解决潜在的疾病机制，而不是下游症状。</p>
</div><p>Fulcrum's most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.</p>
<div class="lb-trans"><p>Fulcrum 最先进的项目包括 FTX-6058，这是一种口服治疗候选药物，旨在提高镰状细胞病和β-地中海贫血患者的胎儿血红蛋白水平，以及一个针对面肩肱肌营养不良症（FSHD）的临床前项目，通过抑制一种关键的表观遗传驱动因子来靶向异常基因表达。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Fulcrum Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Fulcrum Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RlVMQw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=FULC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Fulcrum Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Fulcrum Therapeutics 吗？</h2>
</div><p>Before you consider Fulcrum Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Fulcrum Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fulcrum Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Fulcrum Therapeutics 并不在名单上。</p>
</div><p>While Fulcrum Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Fulcrum Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen

Market Beat

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

2 倍做多纳斯达克生物技术 ETF - ProShares

Fulcrum Therapeutics

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

华尔街 Zen 下调了 Fulcrum Therapeutics（纳斯达克股票代码：FULC）的股票评级